Wyszukaj badanie kliniczne
231 Wyniki
Badanie kliniczne z otwartą rekrutacją
= 
; Badanie kliniczne w toku
= 
; Terminated trial = 
; Ufundowane przez członka IRDiRC = 
; badanie z udziałem członków ERN w co najmniej dwóch krajach członkowskich = 
Krajowe badania kliniczne
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
PHITT: Paediatric Hepatic International Tumour Trial (Phase 3) - AT
Institution: Information not provided - AT
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
LOUVAIN-LA-NEUVE
PHITT: Paediatric Hepatic International Tumour Trial. -BE
Université Catholique de Louvain - UCL
Université catholique de Louvain
CZECHY
Capital City Prague
ADDRESS: NOT PROVIDED - CZ
PHITT: Paediatric Hepatic International Tumour Trial. -CZ
Institution: Information not provided - CZ
FRANCJA
BRETAGNE
RENNES
PHITT: Etude clinique internationale sur les tumeurs hépatiques pédiatriques -FR
CHU de Rennes - Hôpital Pontchaillou
CHU Rennes
NIEMCY
Bayern
MÜNCHEN
PHITT: Internationale pädiatrische Lebertumor-Studie
Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital
Zentrum für Pädiatrische Hämatologie und Onkologie
IRLANDIA
County Dublin
ADDRESS: NOT PROVIDED - IE
PHITT: Paediatric Hepatic International Tumour Trial. -IE
Institution: Information not provided - IE
IZRAEL
ISRAEL
ADDRESS: NOT PROVIDED - IL
PHITT: Paediatric Hepatic International Tumour Trial. -IL
Institution: Information not provided - IL
HOLANDIA
Utrecht
ADDRESS: NOT PROVIDED - NL
PHITT: Paediatric Hepatic International Tumour Trial. -NL
Institution: Information not provided - NL
NORWEGIA
Østlandet
ADDRESS: NOT PROVIDED - NO
PHITT: Paediatric Hepatic International Tumour Trial. -NO
Institution: Information not provided - NO
POLSKA
Gdańsk
GDAŃSK
PHITT: Paediatric Hepatic International Tumour Trial. -PL
Medical University of Gdansk
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
PHITT: Ensayo internacional pediátrico en tumor hepático -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Ensayo fase I de escalado de dosis, multicéntrico, abierto, no aleatorizado, de Regorafenib (BAY 73-4506) en pacientes pediátricos con tumores sólidos malignos recurrentes o refractarios al tratamiento estándar -ES
Institution: Information not provided - ES
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
PHITT: Paediatric Hepatic International Tumour Trial. -CH
Institution: Information not provided - CH
ZJEDNOCZONE KRÓLESTWO
Dorset
BOURNEMOUTH
SIOPEL 4: Intensified Pre-Operative Chemotherapy And Radical Surgery For High Risk Hepatoblastoma (Phase II/III)
Royal Bournemouth Hospital
Department of Haematology
ZJEDNOCZONE KRÓLESTWO
Dorset
BOURNEMOUTH
SIOPEL 6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate in reducing ototoxicity in patients receiving cisplatin chemotherapy for standard risk hepatoblastoma (Phase III) - IE
Royal Bournemouth Hospital
Department of Haematology
ZJEDNOCZONE KRÓLESTWO
Greater London
ADDRESS: NOT PROVIDED - GB
PHITT: Paediatric Hepatic International Tumour Trial. -GB
Institution: Information not provided - GB
HOLANDIA
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Institution: Information not provided - US
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
ACTICCA-1: Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (Phase 3) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
Open-label First Line, Single-arm Phase II Study of CisGem Combined With Pembrolizumab in Patients With Advanced or Metastatic Biliary Tract Cancer - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
FIGHT-302: A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
FORTITUDE-301: A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
CheckMate 459: A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma - AT
Universitätsklinikum - AKH Wien
Klinische Abteilung für Gastroenterologie und Hepatologie
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
ANDERLECHT (BRUSSELS)
Une étude pilote de BMS-936558 avec radiothérapie ablative stéréotaxique après chimiothérapie d'induction dans le cholangiocarcinome - BE
Institut Jules Bordet Instituut
Oncologie digestive
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
FIGHT-202: Étude de phase 2, ouverte, multicentrique, à un seul bras visant à évaluer l'efficacité et la sécurité de l'INCB054828 chez des sujets atteints d'un cholangiocarcinome avancé/métastatique ou inopérable comprenant des translocations impliquant le gène FGFR2 et n'ayant pas répondu aux traitements antérieurs - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
REACHIN: Evaluation des effets de l'administration de Regorafenib chez des patients présentant une tumeur des voies biliaires non opérable et/ou métastatique en progression après gemcitabine et dérivé du platine: une étude de phase II randomisée en double aveugle - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CheckMate 74W: Une étude de phase 3 randomisée, multicentrique, en double aveugle et contrôlée par placebo portant sur le nivolumab et l'ipilimumab, le nivolumab en monothérapie ou le placebo en association avec une chimioembolisation transartérielle (TACE) chez des patients atteints de carcinome hépatocellulaire de stade intermédiaire - BE
Cliniques universitaires Saint-Luc - UCLouvain
Oncologie digestive
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Programme d'extension à long terme du Sorafénib - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
BELGIA
VLAAMS BRABANT
LEUVEN
Een fase 1/2a-onderzoek in 3 delen (fase 1a en fase 1b - dosisescalaties en fase 2a-uitbreiding cohorten) om de veiligheid, verdraagbaarheid, farmacokinetiek en voorlopige antitumoractiviteit van MIV-818 te evalueren bij patiënten met leverkankermanifestaties - BE
UZ Leuven - Campus Gasthuisberg
Digestieve oncologie/Digestive Oncology
FRANCJA
AUVERGNE-RHONE-ALPES
SAINT-ÉTIENNE
AMEBICA : Étude de phase II/III randomisée, évaluant la tolérance et l'efficacité du Folfirinox modifié versus le Gemcis dans les tumeurs des voies biliaires localement évoluées, non résécables et/ou métastatiques
CHU de Saint-Étienne - Hôpital Bellevue
Service de Gastro-entérologie et Hépatologie - Cancérologie digestive
FRANCJA
BRETAGNE
RENNES
An Open-label, Multicenter, Phase II Trial, to Evaluate the Efficacy of Intra-hepatic Administration of Yttrium 90-labelled Microspheres (Therasphere®, Nordion) in Association With Intravenous Chemotherapy With Gemcitabine and Cisplatin for the Treatment of Intra-hepatic Cholangiocarcinoma, First Line. ( Phase II) - FR
CLCC Eugène Marquis
Département d'Oncologie Médicale
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib Plus Erlotinib vs. Sorafenib Plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)
Institution: Information not provided - FR
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (Phase III) - FR
Institution: Information not provided - FR
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
HIPANIV: Étude de phase I évaluant la tolérance et l'efficacité de l'administration intra-artérielle d'ipilimumab en association avec nivolumab par voie intra-veineuse pour le carcinome hépatocellulaire avancé -FR
Institution: Information not provided - FR
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC) -FR
Institution: Information not provided - FR
FRANCJA
OCCITANIE
MONTPELLIER
Neoadjuvant Atezolizumab and Adjuvant Atezolizumab + Bevacizumab in Combination With Percutaneous Radiofrequency Ablation of Small HCC: a Multicenter Randomized Phase II Trial
ICM - Institut régional du Cancer de Montpellier
Service d'oncologie médicale - Médecine B3
FRANCJA
PROVENCE-ALPES-COTE D'AZUR
AVIGNON
FIRST-308 : Étude multicentrique internationale de phase III, randomisée et contrôlée, visant à évaluer l'efficacité et la tolérance du tinengotinib oral par rapport au traitement de choix du médecin chez des patients atteints d'un cholangiocarcinome avec altération FGFR, traité par chimiothérapie et inhibiteur du FGFR -FR
Institut Sainte Catherine
Oncologie médicale
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
PHP-ICC-203: Eine randomisierte, kontrollierte Studie zum Vergleich der Wirksamkeit, Sicherheit und Pharmakokinetik der Melphalan/HDS-Behandlung bei aufeinanderfolgender Anwendung von Cisplatin/Gemcitabin versus Cisplatin/Gemcitabin (Standard of Care) bei Patienten mit intrahepatischem Cholangiokarzinom.
Institution: Information not provided - DE
NIEMCY
Hessen
FRANKFURT AM MAIN
ADJUBIL: Eine Phase-II-Studie zur Immuntherapie mit Durvalumab und Tremelimumab in Kombination mit Capecitabin oder ohne Capecitabin in der adjuvanten Situation bei Gallengangkrebs
Krankenhaus Nordwest GmbH
Institut für Klinische Krebsforschung IKF GmbH
NIEMCY
Niedersachsen
HANNOVER
Phase-II-Studie zur Immuntherapie mit Durvalumab (MEDI4736) oder Durvalumab und Tremelimumab, beide kombiniert mit Y-90 SIRT-Therapie bei fortgeschrittenem intrahepatischen Gallenwegskrebs (BTC)
Medizinische Hochschule Hannover
Klinik für Gastroenterologie, Hepatologie und Endokrinologie
NIEMCY
Niedersachsen
HANNOVER
CheckMate 74W: Eine randomisierte, multizentrische, doppelblinde, placebokontrollierte Phase-III-Studie mit Nivolumab und Ipilimumab, Nivolumab-Monotherapie oder Placebo in Kombination mit transarterieller Chemoembolisation (TACE) bei Patienten mit Leberzellkarzinom (HCC) im Zwischenstadium
Medizinische Hochschule Hannover
Klinik für Gastroenterologie, Hepatologie und Endokrinologie
NIEMCY
Nordrhein-Westfalen
DÜSSELDORF
ProvIDHe: Eine offene, früh zugängliche Phase-3b-Studie mit Ivosidenib bei Patienten mit einem vorbehandelten lokal fortgeschrittenen oder metastasierten Cholangiokarzinom
Universitätsklinikum Düsseldorf
Klinik für Gastroenterologie, Hepatologie und Infektiologie
NIEMCY
Rheinland-Pfalz
MAINZ
Die ABC-HCC Studie:Eine randomisierte, multizentrische, unverblindete klinische Studie der Phase IIIb zur Prüfung der Kombination von Atezolizumab plus Bevacizumab gegen transarterielle Chemoembolisation (TACE) bei Patienten mit intermediären Hepatozellulärem Karzinom
Universitätsmedizin Mainz
I. Medizinische Klinik und Poliklinik
NIEMCY
Sachsen
LEIPZIG
CheckMate 74W: Eine randomisierte, multizentrische, doppelblinde, placebokontrollierte Phase-III-Studie mit Nivolumab und Ipilimumab, Nivolumab-Monotherapie oder Placebo in Kombination mit transarterieller Chemoembolisation (TACE) bei Patienten mit Leberzellkarzinom (HCC) im Zwischenstadium
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie und Infektiologie
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio in aperto di fase I/II per valutare la sicurezza, la tollerabilità e l'efficacia preliminare di durvalumab in monoterapia o in combinazione con tremelimumab in pazienti pediatrici con tumori solidi avanzati e neoplasie ematologiche
Institution: Information not provided - IT
WŁOCHY
LAZIO
ROMA
Studio in aperto, a braccio singolo, di fase 1/2 che valuta la sicurezza e l'efficacia di Ponatinib per il trattamento delle leucemie ricorrenti o refrattarie o dei tumori solidi in pazienti pediatrici
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
JAPONIA
JAPAN
ADDRESS : NOT PROVIDED - JP
TOPAZ-1: A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers - JP
Institution: Information not provided - JP
JAPONIA
JAPAN
ADDRESS : NOT PROVIDED - JP
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Hepatocellular Carcinoma
Institution: Information not provided - JP
JAPONIA
JAPAN
ADDRESS : NOT PROVIDED - JP
Nivolumab and Ipilimumab or Nivolumab or Placebo Plus TACE in Intermediate-stage Liver Cancer (CA20974W)
Institution: Information not provided - JP
JAPONIA
JAPAN
YOKOHAMA
Randomized phase III trial of Sorafenib versus Lenvatinib as a second-line treatment after immune check point inhibitor for advanced hepatocellular carcinoma (JON2102-H (SUCCEED))
Kanagawa Cancer Center
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
KEYNOTE-158: Ensayo clínico de evaluación de biomarcadores predictivos con pembrolizumab (MK-3475) en pacientes con tumores sólidos avanzados -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
FIGHT-302: Estudio en fase III, abierto, aleatorizado, multicéntrico y controlado con tratamiento activo para evaluar la eficacia y la seguridad de pemigatinib comparado con quimioterapia con gemcitabina y cisplatino en el tratamiento de primera línea de participantes con colangiocarcinoma no resecable o metastásico con reordenación del FGFR2 -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Ensayo ABC-HCC: Ensayo en fase IIIb, aleatorizado, multicéntrico y abierto de atezolizumab más bevacizumab frente a quimioembolización transarterial (QETA) en carcinoma hepatocelular en estadio intermedio - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
FOENIX-CCA3: Estudio de fase 3, abierto, aleatorizado, de futibatinib frente a una quimioterapia con cisplatino-gemcitabina como tratamiento de primera línea en pacientes con colangiocarcinoma avanzado con eordenamientos del gen FGFR2 -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
HERIZON-BTC-01: Estudio abierto de Fase 2b de ZW25, de un único grupo de tratamiento en monoterapia, en sujetos con cáncer avanzado o metastásico de las vías biliares con amplificación de HER2 -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
KEYNOTE-966: Estudio de fase 3, aleatorizado y doble ciego de pembrolizumab más gemcitabina/cisplatino en comparación con placebo más gemcitabina/cisplatino como tratamiento de primera línea en participantes con carcinoma de vías biliares avanzado o irresecable - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Un estudio de fase 1/2a realizado en 3 partes (fase 1a y fase 1b de aumento escalonado de la dosis y fase 2a de cohortes de expansión) para evaluar la seguridad, la tolerabilidad, la farmacocinética y la actividad antitumoral preliminar de MIV-818 en pacientes con manifestaciones de cáncer de hígado -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de fase 1/2, abierto y de un solo brazo, que evalúa la seguridad y eficacia del ponatinib para el tratamiento de leucemias o tumores sólidos recurrentes o refractarios en pacientes pediátricos -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
MADRID
FIRST-308: Estudio multicéntrico global, aleatorizado, controlado y de fase III para evaluar la eficacia y seguridad del tinengotinib oral frente a la elección del médico en sujetos con colangiocarcinoma con inhibidor del FGFR, quimioterapia y alteración del FGFR - ES
Hospital Universitario Fundación Jiménez Díaz
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy -GB
Institution: Information not provided - CH
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
CheckMate 74W: A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC) - CH
Institution: Information not provided - CH
ZJEDNOCZONE KRÓLESTWO
Avon
BRISTOL
TOPAZ-1: A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers-GB
Bristol Royal Infirmary
University Hospitals Bristol NHS Foundation Trust HQ
ZJEDNOCZONE KRÓLESTWO
Glasgow
GLASGOW
A Phase 1/2a Study in 3 Parts (Phase 1a and Phase 1b - Dose Escalations and Phase 2a Expansion Cohorts) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients with Liver Cancer Manifestations-GB
Beatson West of Scotland Cancer Centre
ZJEDNOCZONE KRÓLESTWO
Greater Manchester
ADDRESS: NOT PROVIDED - UK
TOPAZ-1: A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers-GB
Institution: Information not provided - UK
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Phase I Study of Single Agent SF1126, a Dual PI3 Kinase and Bromodomain Inhibitor, in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A-B7 Cirrhosis
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
TAS-102 in Treating Advanced Biliary Tract Cancers
Institution: Information not provided - US
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
COSMIC-312: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
EMERALD-2: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
CheckMate 9DW: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
CheckMate 74W: A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
MASTERKEY-318: A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b and to Evaluate the Efficacy and Safety of Intratumoral Talimogene Laherparepvec in Combination With Systemic Pembrolizumab [...] in Phase 2 - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
IMbrave251: A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
The ABC-HCC Trial: A Phase IIIb, Randomized, Multicenter, Open-label Trial of Atezolizumab Plus Bevacizumab Versus Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
OUTREACH2: An Open Label, Randomised Phase 2 Study to Evaluate the Safety and Efficacy of MTL-CEBPA Administered in Combination With Sorafenib or Sorafenib Alone in TKI naïve Participants With Previously Treated Advanced Hepatocellular Carcinoma (HCC) and Hepatitis B or Hepatitis C Virus - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
HBIG-Pilot: Impact of Hepatitis B immunoglobulins in patients with chronic Hepatitis B on Hepatocellular Carcinoma - a proof of concept study - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
STELLAR-002: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
IMbrave050: A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation - AT
Universitätsklinikum - AKH Wien
Klinische Abteilung für Gastroenterologie und Hepatologie
AUSTRIA
WIEN
WIEN
The FAB-HCC Trial: Fecal Microbiota Transplant (FMT) combined with Atezolizumab plus Bevacizumab in Patients with HepatoCellular Carcinoma who failed to respond to prior Immunotherapy - AT
Universitätsklinikum - AKH Wien
Klinische Abteilung für Gastroenterologie und Hepatologie
BELGIA
ANTWERPEN
EDEGEM (ANTWERPEN)
HepaVac-101: Essai de phase I / II portant sur IMA970A plus CV8102 après une perfusion unique de cyclophosphamide avant la vaccination chez des patients présentant un carcinome hépatocellulaire aux stades très précoce, précoce et intermédiaire après tout traitement standard - BE
Antwerp University Hospital - UZA
Dienst gastro-enterologie en hepatologie / Division of Gastroenterology and Hepatology
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
EMERALD-3 : Étude multicentrique de phase III, randomisée, en ouvert, en aveugle pour le promoteur, évaluant durvalumab en association au trémélimumab ± lenvatinib administré en même temps que la CETA par rapport à la CETA seule chez des patients atteints d'un carcinome hépatocellulaire locorégional - BE
Institution: Information not provided - BE
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CheckMate 9DX: Étude randomisée en double aveugle de phase 3 portant sur l'adjuvant nivolumab versus placebo chez des participants atteints d'un carcinome hépatocellulaire présentant un risque élevé de récidive après résection hépatique curative ou ablation - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Des microsphères BioPearl chargées de doxorubicine pour traiter les patients atteints de carcinome hépatocellulaire non résécable: étude de suivi post-commercialisation, multicentrique et à bras unique
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CheckMate 9DW: une étude randomisée, multicentrique, de phase 3 portant sur le nivolumab en association avec l'ipilimumab comparés au sorafenib ou au lenvatinib comme traitement de première intention chez des participants atteints d'un carcinome hépatocellulaire avancé - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CheckMate 9DX: une étude de phase 3, randomisée, en double aveugle portant sur le nivolumab administré en chimiothérapie adjuvante versus placebo pour les participants atteints d'un carcinome hépatocellulaire à haut risque de récidive, après résection ou ablation hépatique à visée curative - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
PRECISION 2: Efficacité de l'Olaparib dans les cancers avancés survenant chez des patients présentant des mutations germinales ou des mutations tumorales somatiques dans un des gènes de recombinaison homologue, une étude belge de type "panier" de phase II
Universitair Ziekenhuis Brussel
Oncologisch centrum
BELGIA
OOST-VLAANDEREN
GENT
TRACE: Radioembolisation transartérielle versus chimioembolisation transartérielle pour le traitement du carcinome hépatocellulaire (CHC): un essai contrôlé randomisé multicentrique
Ghent University Hospital - UZ Gent
Radiologie
BELGIA
VLAAMS BRABANT
LEUVEN
IMbrave251: Une étude de phase III, ouverte et randomisée, de l'atezolizumab en combinaison avec le lenvatinib ou le sorafénib par rapport au lenvatinib ou au sorafenib seuls dans le carcinome hépatocellulaire préalablement traité par l'atezolizumab et le bévacizumab - BE
UZ Leuven - Campus Gasthuisberg
Dienst maag-, darm- en leverziekten (gastro-enterologie en hepatologie)
KANADA
Québec
ADDRESS: NOT PROVIDED - CA
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma - CA
Institution: Information not provided - CA
KANADA
Québec
ADDRESS: NOT PROVIDED - CA
HIMALAYA: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma - CA
Institution: Information not provided - CA
KANADA
Québec
ADDRESS: NOT PROVIDED - CA
CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation-CA
Institution: Information not provided - CA
KANADA
Québec
ADDRESS: NOT PROVIDED - CA
EMERALD-3: A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma -CA
Institution: Information not provided - CA
FRANCJA
AUVERGNE-RHONE-ALPES
LYON
SOMAPROTECT01 : Evaluation de l'ascite postopératoire après perfusion de somatostatine au cours des hépatectomies par laparotomie pour carcinome hépatocellulaire : Etude randomisée multicentrique en double aveugle versus placebo (Phase III)
CHU de Lyon HCL - GH Nord-Hôpital de la Croix Rousse
Service de chirurgie générale, digestive et transplantations hépatiques et intestinales
FRANCJA
BOURGOGNE-FRANCHE-COMTE
BESANÇON
TERTIO : Evaluation de l'intérêt de combiner un vaccin inducteur de CD4-Th1 dérivé de la télomérase avec un traitement par atezolizumab et bevacizumab chez des patients avec un cancer hépatocellulaire non résécable : une étude de phase II randomisée pour la preuve du concept -FR
CHU de Besançon - Hôpital Jean Minjoz
Service d'oncologie médicale
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Institution: Information not provided - FR
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
RESORCE: A randomized, double blind, placebo-controlled, multicenter phase III study of Regorafenib in patients with Hepatocellular Carcinoma after Sorafenib - FR
Institution: Information not provided - FR
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Étude de preuve de concept relative à l'efficacité du P03277 dans l'imagerie par résonance magnétique pour le diagnostic du carcinome hépatocellulaire (Phase IIa)
Institution: Information not provided - FR
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Etude de phase 3 prospective, randomisée, en aveugle et contrôlée des microsphères HépaSphere / QuadraSphere pour l'administration de la doxorubicine dans le traitement du carcinome hépatocellulaire - FR
Institution: Information not provided - FR
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE for patients with intermediate stage HCC - FR
Institution: Information not provided - FR
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
An Open-Label Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC) After PD1/PD-L1 Immune Checkpoint Inhibitors -FR
Institution: Information not provided - FR
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
EMERALD-3 : Étude multicentrique de phase III, randomisée, en ouvert, en avuegle pour le promoteur, évaluant durvalumab en association au trémélimumab ± lenvatinib administré en même temps que la CETA par rapport à la CETA seule chez les patients atteints d'un carcinome hépatocellulaire locorégional. -FR
Institution: Information not provided - FR
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
MOIO : Essai randomisé de phase III d'une immunothérapie (IO) standard par des inhibiteurs de points de contrôle,versus une intensité de dose réduite d'IO chez des patients atteints de cancer métastatique en réponse après 6 mois d'IO standard -FR
Institution: Information not provided - FR
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Etude de première administration chez l'Homme, de phase 1/2 avec escalade de dose des cellules T BOXR1030 chez des sujets atteints d'une tumeur solide avancée GPC3-Positive -FR
Institution: Information not provided - FR
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
TRIPLET : Étude de phase II-III randomisée, en ouvert, évaluant les avantages de l'ajout de l'ipilimumab à l'association d'atezolizumab et de bevacizumab chez les patients atteints de carcinome hépatocellulaire recevant un traitement systémique de première intention. -FR
Institution: Information not provided - FR
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
HOLMBRAVE : Étude clinique évaluant la tolérance et l'efficacité d'une radiothérapie sélective intra-artérielle au 166Holmium en association avec l'atezolizumab et le bevacizumab pour le carcinome hépatocellulaire non résécable.
Institution: Information not provided - FR
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
SIERRA : étude de phase IIIb, en ouvert et multicentrique, évaluant Durvalumab et Tremelimumab en traitement de première ligne chez les patients atteints d'un carcinome hépatocellulaire avancé - FR
Institution: Information not provided - FR
FRANCJA
HAUTS-DE-FRANCE
LILLE
Etude multicentrique de phase I/II en ouvert évaluant FGF401 administré par voie orale à des patients adultes atteints de carcinome hépatocellulaire ou de tumeurs solides exprimant FGFR4 et KLB - FR
CHRU de Lille - Hôpital Claude Huriez
Service des Maladies de l'appareil digestif et nutrition - Hépatologie
FRANCJA
ILE-DE-FRANCE
CRÉTEIL
TACERTE : Efficacité de l'association de la radiothérapie conformationnelle à haute dose et de la chimioembolisation intra-artérielle hépatique dans le traitement du carcinome hépatocellulaire (Phase II)
Hôpitaux Universitaires Henri Mondor
Service d'Hépatologie
FRANCJA
NOUVELLE AQUITAINE
BORDEAUX
PRODIGE 21 : Essai de phase II randomisé évaluant l'administration de sorafenib ou de pravastatine ou de l'association sorafenib-pravastatine ou des soins de confort pour le traitement palliatif du carcinome hépatocellulaire sur cirrhose Child B.
CHU - Hôpitaux de Bordeaux
Direction de la Recherche Clinique et de l'Innovation (DRCI) - Hôpitaux de Bordeaux
NIEMCY
Baden-Württemberg
TÜBINGEN
CheckMate 459: Eine randomisierte, multizentrische Phase III-Studie zu Nivolumab versus Sorafenib als First-Line Therapie von Patienten mit fortgeschrittenem Hepatozellulären Karzinom
Department für Innere Medizin - Medizinische Universitätsklinik Tübingen
Innere Medizin I - Gastroenterologie, Hepatologie und Infektiologie
NIEMCY
Bayern
MÜNCHEN
CheckMate 9DX: Eine randomisierte, doppelblinde Phase-3-Studie von Adjuvant Nivolumab versus Placebo für Teilnehmer mit hepatozellulärem Karzinom, die ein hohes Rezidivrisiko nach kurativer hepatischer Resektion oder Ablation haben
Geschäftsstelle CCC München
CCC München - Comprehensive Cancer Center
NIEMCY
Bayern
MÜNCHEN
DEMAND: Randomisierte, zweiarmige, nicht vergleichende Phase II Studie zur Wirksamkeit von Atezolizumab und Roche Bevacizumab (Atezo/Bev) gefolgt von selektiver TACE nur bei Bedarf (sdTACE) im Falle von Krankheitsprogression oder initial synchroner Behandlung mit TACE und Atezo/Bev auf die 24-Monate-Überlebensrate bei der Behandlung von Patienten mit nicht resektablem HCC
LMU Klinikum der Universität München - Campus Großhadern
Medizinische Klinik und Poliklinik II
NIEMCY
Bayern
WÜRZBURG
CheckMate 9DX: Eine randomisierte, doppelblinde Phase-3-Studie von Adjuvant Nivolumab versus Placebo für Teilnehmer mit hepatozellulärem Karzinom, die ein hohes Rezidivrisiko nach kurativer hepatischer Resektion oder Ablation haben
Zentrum Innere Medizin (ZIM)
Medizinische Klinik und Poliklinik II
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
HIMALAYA: Eine randomisierte, offene, multizentrische Phase-III-Studie mit Durvalumab und Tremelimumab als Erstlinientherapie bei Patienten mit fortgeschrittenem Hepatozellulärem Karzinom
Institution: Information not provided - DE
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
ARTISTRY-2: Eine Phase-1/2-Studie mit ALKS 4230, subkutan als Monotherapie und in Kombination mit Pembrolizumab bei Probanden mit fortgeschrittenen soliden Tumoren verabreicht
Institution: Information not provided - DE
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
Eine offene Studie mit Regorafenib in Kombination mit Pembrolizumab bei Patienten mit fortgeschrittenem oder metastasiertem hepatozellulärem Karzinom (HCC) nach PD-1/PD-L1-Immun-Checkpoint-Inhibitoren
Institution: Information not provided - DE
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
EMERALD-3: Eine randomisierte, offene, vom Sponsor verblindete, multizentrische Phase-III-Studie zu Durvalumab in Kombination mit Tremelimumab ± Lenvatinib, die gleichzeitig mit TACE verabreicht wird, im Vergleich zu TACE allein bei Patienten mit lokal begrenztem hepatozellulärem Karzinom
Institution: Information not provided - DE
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
SIERRA: Eine einarmige, offene, multizentrische Phase-IIIb-Studie mit Durvalumab und Tremelimumab als Erstlinienbehandlung bei Teilnehmern mit fortgeschrittenem Leberzellkarzinom
Institution: Information not provided - DE
NIEMCY
Hessen
FRANKFURT AM MAIN
SOLARIS: Eine offene Phase-II-Studie mit Pembrolizumab und Lenvatinib bei Patienten mit fortgeschrittenem hepatozellulärem Karzinom, die refraktär auf eine Therapie mit Atezolizumab und Bevacizumab / IO sind
Krankenhaus Nordwest GmbH
Institut für Klinische Krebsforschung IKF GmbH
NIEMCY
Niedersachsen
HANNOVER
CheckMate 9DX: Eine randomisierte, doppelblinde Phase-3-Studie von Adjuvant Nivolumab versus Placebo für Teilnehmer mit hepatozellulärem Karzinom, die ein hohes Rezidivrisiko nach kurativer hepatischer Resektion oder Ablation haben
Medizinische Hochschule Hannover
Klinik für Gastroenterologie, Hepatologie und Endokrinologie
NIEMCY
Niedersachsen
HANNOVER
IMMUWIN: Eine Phase-II-Studie zur Immuntherapie mit Durvalumab (MEDI4736) und Tremelimumab in Kombination mit entweder Y-90 SIRT oder TACE bei Patienten mit Leberzellkarzinom im Zwischenstadium mit einem 'Pick-the-Winner'-Design
Medizinische Hochschule Hannover
Klinik für Gastroenterologie, Hepatologie und Endokrinologie
NIEMCY
Nordrhein-Westfalen
KÖLN
Eine randomisierte, offene, multizentrische Phase-3-Studie zum Vergleich der Wirksamkeit und Sicherheit von BGB-A317 mit Sorafenib als Erstlinienbehandlung bei Patienten mit unresektierbarem hepatozellulärem Karzinom
Universitätsklinikum Köln
NIEMCY
Sachsen
DRESDEN
CaPture: Cabozantinib-Behandlung in einer Phase-II-Studie für Patienten mit hepatozellulärem Karzinom (HCC), bei denen eine Behandlung mit einem PD-1- oder PD-L1-Inhibitor nicht erfolgreich war
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I
NIEMCY
Sachsen
LEIPZIG
CaPture: Cabozantinib-Behandlung in einer Phase-II-Studie für Patienten mit hepatozellulärem Karzinom (HCC), bei denen eine Behandlung mit einem PD-1- oder PD-L1-Inhibitor nicht erfolgreich war
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie und Infektiologie
IRLANDIA
County Dublin
DUBLIN
TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE for patients with intermediate stage HCC - IE
St. Vincent's University Hospital
Department of Oncology
IRLANDIA
County Dublin
DUBLIN
TACE-2 - A randomised placebo-controlled, double blinded, phase III trial of sorafenib in combination with transarterial chemoembolisation in hepatocellular cancer - IE
St. Vincent's University Hospital
Radiology Department
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
EVOLVE-1 : Studio di fase III, multicentrico, randomizzato, in doppio cieco, contro placebo, per valutare l'efficacia e la tolleranza di Everolimus (RAD001) in pazienti adulti affetti da carcinoma epatocellulare avanzato già trattati in precedenza con Sorafenib - IT
Institution: Information not provided - IT
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio sulla sicurezza, tollerabilità e attività clinica di MEDI4736 e Tremelimumab somministrati in monoterapia e in combinazione a soggetti con carcinoma epatocellulare non resecabile - IT
Institution: Information not provided - IT
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Efficacia e sicurezza di Cabozantinib in pazienti con carcinoma epatocellulare in progressione o intolleranti a un precedente trattamento con inibitori del checkpoint immunologico: uno studio di fase II (Immunocabo)
Institution: Information not provided - IT
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio di fase IIIb, a singolo braccio, multicentrico, su Atezolizumab (Tecentriq) in associazione a Bevacizumab per valutare la sicurezza e l'efficacia in pazienti affetti da carcinoma epatocellulare non operabile, non precedentemente trattato con terapia sistemica
Institution: Information not provided - IT
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
EMERALD-3: studio di fase III, randomizzato, in aperto, in cieco, multicentrico su Durvalumab in associazione con Tremelimumab ± Lenvatinib somministrato in concomitanza con TACE rispetto a TACE da solo in pazienti con carcinoma epatocellulare
Institution: Information not provided - IT
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
SIERRA: uno studio di fase IIIb a braccio singolo, in aperto, multicentrico su durvalumab e tremelimumab come trattamento di prima linea in partecipanti con carcinoma epatocellulare avanzato
Institution: Information not provided - IT
WŁOCHY
LOMBARDIA
MILANO
NEOTOMA: Terapia perioperatoria con Durvalumab più Tremelimumab in pazienti con carcinoma epatocellulare resecabile (HCC) - Uno studio di fase II
Fondazione IRCCS Istituto Nazionale dei Tumori
S.C. Chirurgia Generale Indirizzo Oncologico 1 (Epato-gastro-pancreatico e Trapianto di Fegato)
WŁOCHY
LOMBARDIA
MILANO
Studio di fase I/II sulla sicurezza e l'efficacia di NMS-01940153E in pazienti adulti con carcinoma epatocellulare (HCC) non resecabile precedentemente trattati con terapia sistemica
Fondazione IRCCS Istituto Nazionale dei Tumori
S.C. Oncologia Medica 1
JAPONIA
JAPAN
ADDRESS : NOT PROVIDED - JP
EMERALD-1: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma - JP
Institution: Information not provided - JP
JAPONIA
JAPAN
ADDRESS : NOT PROVIDED - JP
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors - JP
Institution: Information not provided - JP
JAPONIA
JAPAN
ADDRESS : NOT PROVIDED - JP
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab - JP
Institution: Information not provided - JP
HISZPANIA
Cataluña
BARCELONA
Estudio GOING: Regorafenib seguido del Nivolumab en pacientes con progresión de la enfermedad tratados con sorafenib - ES
Hospital Clínic de Barcelona
Servicio de Hepatología
HISZPANIA
Cataluña
BARCELONA
Estudio de fase I/II para evaluar la seguridad y eficacia de NMS-01940153E en pacientes adultos con carcinoma hepatocelular (CHC) irresecable previamente tratados con terapia sistémica -ES
Hospital Clínic de Barcelona
Servicio de Hepatología
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
HEPANOVA: Ensayo de fase II de los campos de tratamiento del tumor (TTFfields, 150 kHz) concomitante con sorafenib para el carcinoma hepatocelular avanzado (CHC) - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Ensayo de fase I/II, para evaluar la farmacocinética, en múltiples tumores, de la formulación subcutánea de Nivolumab en monoterapia - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de Fase 3, aleatorizado, abierto y multicéntrico, comparativo de la eficacia y la seguridad de BGB A317 frente a sorafenib como tratamiento de primera línea en pacientes con carcinoma hepatocelular no resecable - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
CheckMate 9DX: Estudio en fase III, aleatorizado y doble ciego de nivolumab adyuvante frente a placebo para participantes con carcinoma hepatocelular que presentan un riesgo alto de recaída después de la resección o la ablación hepática con intención curativa (Evaluación en ensayo clínico de la vía de punto de control y el nivolumab 9DX) - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
HIMALAYA: Ensayo Fase III, aleatorizado, abierto, multicéntrico de durvalumab y tremelimumab como tratamiento en primera línea en pacientes con Carcinoma Hepatocelular Irresecable -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
COSMIC-312: Estudio de fase III aleatorizado y controlado de cabozantinib (XL184) combinado con atezolizumab frente a sorafenib en pacientes con carcinoma hepatocelular avanzado que no han recibido ningún tratamiento antineoplásico sistémico anterior -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio sin enmascaramiento de regorafenib en combinación con pembrolizumab en pacientes con carcinoma hepatocelular (CHC) avanzado o metastásico después del tratamiento con inhibidores del punto de control inmunitario PD-1/PD-L1 - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
IMbrave251: Estudio de fase III, abierto y aleatorizado de atezolizumab con lenvatinib o sorafenib en comparación con lenvatinib o sorafenib en monoterapia en carcinoma hepatocelular tratado previamente con atezolizumab y bevacizumab - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
EMERALD-3: Ensayo fase III, aleatorizado, abierto, ciego para el promotor y multicéntrico, de durvalumab en combinación con tremelimumab ± lenvatinib administrados simultáneamente con quimioembolización transarterial (TACE) en comparación con TACE sola en pacientes con carcinoma hepatocelular locorregional - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Ensayo fase 2, aleatorizado, abierto, de relatlimab en combinación con nivolumab en pacientes con carcinoma hepatocelular avanzado naive a tratamientos inmuno-oncológicos, que han progresado a inhibidores de la tirosina quinasa -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio clínico de fase 3, multicéntrico, aleatorizado, doble ciego y con control activo para evaluar la seguridad y la eficacia de lenvatinib (E7080/MK-7902) con pembrolizumab (MK-3475) en combinación con quimioembolización transarterial (QETA) en comparación con QETA en participantes con carcinoma hepatocelular no metastásico incurable (LEAP-012) -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
KEYNOTE-937: Estudio de fase 3, doble ciego, con dos grupos, para evaluar la seguridad y la eficacia de pembrolizumab (MK-3475) frente a un placebo como tratamiento adyuvante en participantes con carcinoma hepatocelular y respuesta radiológica completa tras resección quirúrgica o ablación local -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio clínico fase 2 y multicéntrico para evaluar la seguridad y la eficacia de MK-1308A (coformulación de MK-1308/MK-3475) en combinación con lenvatinib (E7080/MK-7902) en el tratamiento de primera línea de participantes con carcinoma hepatocelular avanzado -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
EMERALD-1: Ensayo fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la combinación de quimioembolización transarterial (TACE) con durvalumab en monoterapia o con durvalumab más bevacizumab en pacientes con carcinoma hepatocelular que requieran tratamiento locorregional -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
SIERRA: Estudio multicéntrico, abierto, de un solo grupo de fase IIIb de Durvalumab y Tremelimumab como tratamiento de primera línea en participantes con carcinoma hepatocelular avanzado -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio clínico de fase III aleatorizado, abierto, internacional, multicéntrico, del anticuerpo PD-1 SHR-1210 más mesilato de apatinib (Rivoceranib) en comparación con Sorafenib como tratamiento de primera línea en pacientes con carcinoma hepatocelular (CHC) avanzado que no han recibido previamente tratamiento sistémico -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
CheckMate 9DW: Estudio aleatorizado, multicéntrico, de fase III de nivolumab en combinación con ipilimumab en comparación con lenvatinib o sorafenib como tratamiento de primera línea en participantes con carcinoma hepatocelular avanzado - ES
Institution: Information not provided - ES
HISZPANIA
Navarra
PAMPLONA
NEOTOMA: Terapia perioperatoria con Durvalumab más Tremelimumab para pacientes con carcinoma hepatocelular (HCC) resecable: un ensayo de fase II -ES
Clínica Universidad de Navarra
Unidad de Hepatología
SZWECJA
Region Uppsala
UPPSALA
An open, single center two-step trial (A+B), comparing the safety and tolerability of idarubicin 10 mg and 15 mg after separate single hepatic intra-arterial injections of a drug formulation based on lipiodol emulsion in patients with unilobular or bilobular intermediate stage hepatocellular carcinoma. - SE
Uppsala Universitet
Department of Surgical Sciences
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
PRIME-HCC: Preliminary Assessment of Safety and Bioactivity of the Ipilimumab and Nivolumab Combination Prior to Liver Resection (LR) in Hepatocellular Carcinoma (HCC) GB
Imperial College NHS Trust
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation-GB
King's College Hospital
King's College Hospital NHS Foundation Trust HQ
ZJEDNOCZONE KRÓLESTWO
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma - GB
Institution: Information not provided - UK
STANY ZJEDNOCZONE AMERYKI
Arizona
SCOTTSDALE
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC) - US
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
Institution: Information not provided - US
Wieloośrodkowe badania kliniczne
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase I Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma, or Other Tumors Potentially Dependent on Hedgehog Signaling Pathway
Institution: Information not provided - CH
ZJEDNOCZONE KRÓLESTWO
West Midlands
BIRMINGHAM
PHITT: Paediatric Hepatic International Tumour Trial
Birmingham Children's Hospital NHS Foundation Trust
Department of Oncology
DANIA
Fyn
ODENSE
Nordic-BTC-01: Neoadjuvant chemotherapy in patients with biliary tract carcinomas - A Nordic phase II study
Odense University hospital
Research Department of Clinical Oncology
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Open-label first line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer
EORTC
European Organisation for the Research and Treatment of Cancer
CHINY
CHINA
ADDRESS: NOT PROVIDED - CN
FIRST-308: A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib VS Physician's Choice in Subjects With FGFR-altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma.
Institution: Information not provided - CN
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib versus Sorafenib plus Placebo as first line treatment for Hepatocellular Carcinoma (HCC) (coordination)
Institution: Information not provided - DE
SZWECJA
Region Stockholm
ADDRESS: NOT PROVIDED - SE
A Phase 1/2a Study in 3 Parts (Phase 1a and Phase 1b - Dose Escalations and Phase 2a Expansion Cohorts) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients with Liver Cancer Manifestations
Institution: Information not provided - SE
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
FIGHT-202: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy
Institution: Information not provided - CH
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A First In Human, Open Label, Dose Escalation Phase I Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Clinical Activity Profile Of Single Agent RO7119929 (TLR7 Agonist) Administered Orally To Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Institution: Information not provided - CH
STANY ZJEDNOCZONE AMERYKI
Delaware
WILMINGTON
STANY ZJEDNOCZONE AMERYKI
Indiana
INDIANAPOLIS
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company World Headquarters
STANY ZJEDNOCZONE AMERYKI
New Jersey
RAHWAY
KEYNOTE 158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors
Merck, Sharp & Dohme Corp.
STANY ZJEDNOCZONE AMERYKI
Pennsylvania
PHILADELPHIA
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma (Coordination)
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
KEYNOTE-240: A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1/2, MultiCenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability and Preliminary Efficacy of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellullar Carcinoma (HCC) Following First Line Treatment Failure
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
TOPAZ-1: A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
PROCLAIM-CX-2009: A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Phase III, Open-Label, Randomized Study of On-Demand TACE Combined With Atezolizumab Plus Bevacizumab (Atezo/Bev) or On-Demand TACE Alone in Patients With Untreated Heaptocellular Carcionma
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
CheckMate 74W: A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
FOENIX-CCA3: A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors
Institution: Information not provided - US
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
TRACE Trial: Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of HCC: A Multicenter Randomized Controlled Trial
Institution: Information not provided - BE
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation
Institution: Information not provided - BE
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CheckMate 9DW: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma
Bristol Myers Squibb International Corporation
KANADA
Ontario
TORONTO
NEOTOMA: Perioperative Therapy With Durvalumab Plus Tremelimumab for Patients With Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial.
Toronto General Hospital
University Health Network (UHN)
FRANCJA
ILE-DE-FRANCE
RUEIL-MALMAISON
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study) (coordination)
Bristol Myers Squibb France
Bristol-Myers Squibb France
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
RESORCE: A randomized, double blind, placebo-controlled, multicenter phase III study of Regorafenib in patients with Hepatocellular Carcinoma after Sorafenib
Institution: Information not provided - DE
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Institution: Information not provided - DE
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
YES-P: A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT) (Phase III)
Institution: Information not provided - DE
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Institution: Information not provided - DE
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
SORAMIC: Evaluation of sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma
Institution: Information not provided - DE
IZRAEL
ISRAEL
ADDRESS: NOT PROVIDED - IL
A Phase 2 Study in the Second-Line Treatment of Advanced Hepatocellular Carcinoma in Subjects With Child-Pugh Class B Cirrhosis
Institution: Information not provided - IL
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
HepaVac-101: A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments
Institution: Information not provided - IT
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Phase I/II Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy.
Institution: Information not provided - IT
HOLANDIA
Utrecht
ADDRESS: NOT PROVIDED - NL
A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects With Unresectable Hepatocellular Carcinoma
Institution: Information not provided - NL
HISZPANIA
Navarra
PAMPLONA
EMERALD-1: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma
Clínica Universidad de Navarra
SZWECJA
Region Stockholm
ADDRESS: NOT PROVIDED - SE
HIMALAYA: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Institution: Information not provided - SE
SZWECJA
Region Stockholm
SÖDERTALJE
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
IMbrave251: A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
Institution: Information not provided - CH
ZJEDNOCZONE KRÓLESTWO
Greater London
ADDRESS: NOT PROVIDED - GB
TACE-2 - A randomised placebo-controlled, double blinded, phase III trial of sorafenib in combination with transarterial chemoembolisation in hepatocellular cancer
Institution: Information not provided - GB
ZJEDNOCZONE KRÓLESTWO
Greater London
SURREY
A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumor.
The Royal Marsden
Royal Marsden NHS Foundation Trust
ZJEDNOCZONE KRÓLESTWO
Greater Manchester
ADDRESS: NOT PROVIDED - UK
TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE for patients with intermediate stage HCC
Institution: Information not provided - UK
STANY ZJEDNOCZONE AMERYKI
California
PLEASANTON
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Astex Pharmaceuticals, Inc
STANY ZJEDNOCZONE AMERYKI
Utah
SOUTH JORDAN
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Merit Medical Systems, Inc.
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
REACH: A multicenter, randomized, double-blind, phase 3 study of ramucirumab (imc-1121b) drug product and best supportive care (BSC) versus placebo and BSC as second-line treatment in patients with hepatocellular carcinoma following first-line therapy with sorafenib
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
METIV-HCC: A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Randomized controlled phase II trial of ARQ 197 in patients with unresectable Hepatocellular Carcinoma (HCC) who have failed one prior systemic therapy
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Multicenter, Global, Randomized, Double-blind Study Of Axitinib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients With Advanced Hepatocellular Carcinoma Following Failure Of One Prior Antiangiogenic Therapy
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A phase I/II, multicenter, open-label study of oral FGF401 in adult patients with hepatocellular carcinoma or solid malignancies characterized by positive FGFR4 and KLB expression
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 Versus Sorafenib as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma.
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
ARTISTRY-2: A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
An Open-Label Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC) After PD1/PD-L1 Immune Checkpoint Inhibitors
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
EMERALD-3: A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma.
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US